COMPANY PROFILE

Bio-Engine / 倍谙基

Explore full profile

Shanghai serum-free chemically defined cell-culture media OEM

ChinaFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bio-Engine / 倍谙基

Bio-Engine / 倍谙基 (Shanghai BioEngine / 上海倍谙基生物科技) is a Shanghai serum-free and chemically defined cell-culture media OEM founded in 2014. The company supplies CHO, Vero, HEK293 and immune-cell media plus process development for antibody, vaccine and CGT manufacturers, with Minhang Pujiang R&D and a Jinshan GMP powder plant. Mid-size China cell-culture media leftover beyond ExCell mandate soft-skip, Tianhang and Procell size soft-skips, and Pack 38 reagent set — city-level Shanghai HQ (not Huangpu district pin); CN site bio-engine.com.cn documented alongside existing bioengine-global.com domain.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: China
Employees: 18
Open positions: None listed
Dealroom signal: 40.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	May 2023	$41M	$248M	Addor Capital · LEO Group · Huimei Technology · River Head Capital	↗
SERIES BEquity / VC	Aug 2019	—	—	Shenzhen Guozhong Venture Capital Management	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Bio-Engine / 倍谙基 website traffic

Latest recorded traffic for Bio-Engine / 倍谙基 is 160 monthly website visits, down 70.4% over the last three months. Bio-Engine / 倍谙基's team grew 0% over the past year.

Latest monthly visits160 3-month web change-70.4% 1-year team growth0%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
FAFabentechSpecializes in the development and production of emergency treatments to combat the risks of bioterrorism and emerging infectious diseases that are priorities for public health	Lyon, France	Operational